BIIB RSI Chart
Last 7 days
2.0%
Last 30 days
7.4%
Last 90 days
-8.9%
Trailing 12 Months
-30.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 9.7B | 0 | 0 | 0 |
2023 | 10.1B | 10.0B | 10.0B | 9.8B |
2022 | 10.8B | 10.6B | 10.4B | 10.2B |
2021 | 12.6B | 11.7B | 11.1B | 11.0B |
2020 | 14.4B | 14.5B | 14.3B | 13.4B |
2019 | 13.8B | 14.1B | 14.2B | 14.4B |
2018 | 12.6B | 12.9B | 13.2B | 13.5B |
2017 | 11.5B | 11.7B | 11.8B | 12.3B |
2016 | 10.9B | 11.2B | 11.4B | 11.4B |
2015 | 10.1B | 10.3B | 10.6B | 10.8B |
2014 | 7.6B | 8.3B | 9.0B | 9.7B |
2013 | 5.6B | 5.9B | 6.4B | 6.9B |
2012 | 5.1B | 5.3B | 5.4B | 5.5B |
2011 | 4.8B | 4.8B | 4.9B | 5.0B |
2010 | 4.4B | 4.6B | 4.6B | 4.7B |
2009 | 4.2B | 4.3B | 4.3B | 4.4B |
2008 | 0 | 3.5B | 3.8B | 4.1B |
2007 | 0 | 0 | 0 | 3.2B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | keeney adam | sold (taxes) | -59,651 | 216 | -276 | head of corporate development |
May 01, 2024 | keeney adam | acquired | - | - | 938 | head of corporate development |
Apr 02, 2024 | singhal priya | sold | -19,817 | 213 | -93.00 | head of development |
Apr 01, 2024 | murphy nicole | acquired | - | - | 240 | head of pharm ops and tech |
Apr 01, 2024 | murphy nicole | sold (taxes) | -25,135 | 214 | -117 | head of pharm ops and tech |
Feb 22, 2024 | singhal priya | sold | -57,962 | 221 | -262 | head of development |
Feb 16, 2024 | gregory ginger | acquired | - | - | 4,704 | evp, human resources |
Feb 16, 2024 | alexander susan h | acquired | - | - | 5,037 | evp chief legal officer |
Feb 16, 2024 | murphy nicole | sold (taxes) | -133,639 | 219 | -610 | head of pharm ops and tech |
Feb 16, 2024 | izzar rachid | acquired | - | - | 2,017 | head of global product strat. |
Which funds bought or sold BIIB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 06, 2024 | DUALITY ADVISERS, LP | new | - | 1,289,680 | 1,289,680 | 0.13% |
May 06, 2024 | LCM Capital Management Inc | sold off | -100 | -239,103 | - | -% |
May 06, 2024 | AIA Group Ltd | reduced | -6.33 | -88,776 | 315,682 | 0.01% |
May 06, 2024 | HighTower Advisors, LLC | added | 2.25 | -550,000 | 3,022,000 | -% |
May 06, 2024 | DiNuzzo Private Wealth, Inc. | reduced | -13.33 | -1,078 | 2,804 | -% |
May 06, 2024 | Wealthspire Advisors, LLC | reduced | -12.56 | -167,146 | 448,727 | 0.01% |
May 06, 2024 | Integrated Advisors Network LLC | added | 107 | 151,705 | 359,244 | 0.02% |
May 06, 2024 | IFG Advisory, LLC | sold off | -100 | -460,350 | - | -% |
May 06, 2024 | Envestnet Portfolio Solutions, Inc. | added | 2.36 | -122,480 | 710,501 | -% |
May 06, 2024 | GREAT VALLEY ADVISOR GROUP, INC. | added | 37.44 | 104,463 | 825,892 | 0.03% |
Unveiling Biogen Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Biogen Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 357.8B | 85.6B | 9.3 | 4.18 | ||||
MRK | 330.2B | 61.4B | 143.19 | 5.38 | ||||
AMGN | 161.1B | 29.5B | 42.82 | 5.46 | ||||
PFE | 156.8B | 46.5B | -112.94 | 3.37 | ||||
GILD | 81.5B | 27.1B | 14.39 | 3.01 | ||||
TEVA | 15.6B | 15.8B | -27.14 | 0.99 | ||||
MID-CAP | ||||||||
ALKS | 4.2B | 1.7B | 9.58 | 2.41 | ||||
PRGO | 4.1B | 4.6B | -533.77 | 0.9 | ||||
BHC | 2.7B | 9.0B | -5.97 | 0.3 | ||||
AMPH | 2.1B | 644.4M | 14.96 | 3.19 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.38 | 2.07 | ||||
TXMD | 23.2M | 1.3M | -2.26 | 17.8 | ||||
ACRX | 17.0M | - | -0.92 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Biogen Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -4.0% | 2,291 | 2,386 | 2,530 | 2,456 | 2,463 | 2,544 | 2,509 | 2,589 | 2,532 | 2,734 | 2,779 | 2,775 | 2,694 | 2,853 | 3,376 | 3,682 | 3,534 | 3,671 | 3,600 | 3,617 | 3,490 |
Costs and Expenses | -12.8% | 1,826 | 2,095 | 2,672 | 1,748 | 2,025 | 1,940 | 1,137 | 1,320 | 2,184 | 2,582 | 2,488 | 2,193 | 1,720 | 2,686 | 2,290 | 1,707 | 1,714 | 1,894 | 1,794 | 1,661 | 1,987 |
S&GA Expenses | -4.4% | 582 | 609 | 788 | 548 | 605 | 633 | 563 | 573 | 635 | 788 | 654 | 637 | 595 | 806 | 573 | 555 | 570 | 665 | 555 | 588 | 568 |
EBITDA Margin | 3.9% | 0.22* | 0.21* | 0.23* | 0.38* | 0.44* | 0.43* | 0.40* | 0.29* | 0.22* | 0.23* | 0.21* | 0.26* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -3.2% | 69.00 | 72.00 | 64.00 | 49.00 | 63.00 | 55.00 | 60.00 | 66.00 | 66.00 | 66.00 | 66.00 | 56.00 | 65.00 | 56.00 | 56.00 | 66.00 | 44.00 | 46.00 | 46.00 | 48.00 | 48.00 |
Income Taxes | 67.2% | 71.00 | 43.00 | -72.90 | 115 | 51.00 | 54.00 | 236 | 217 | 126 | 443 | -25.90 | -409 | 44.00 | 13.00 | 241 | 446 | 292 | 276 | 211 | 248 | 423 |
Earnings Before Taxes | 59.4% | 465 | 292 | -141 | 708 | 438 | 604 | 1,371 | 1,270 | 347 | 405 | 291 | 582 | 467 | 353 | 958 | 2,038 | 1,699 | 1,728 | 1,779 | 1,759 | 1,860 |
EBT Margin | 1.8% | 0.13* | 0.13* | 0.16* | 0.31* | 0.36* | 0.35* | 0.33* | 0.22* | 0.15* | 0.16* | 0.15* | 0.20* | - | - | - | - | - | - | - | - | - |
Net Income | 57.5% | 393 | 250 | -68.10 | 592 | 388 | 550 | 1,135 | 1,058 | 304 | 368 | 329 | 449 | 410 | 358 | 702 | 1,542 | 1,399 | 1,440 | 1,546 | 1,494 | 1,409 |
Net Income Margin | 2.3% | 0.12* | 0.12* | 0.15* | 0.27* | 0.31* | 0.30* | 0.28* | 0.19* | 0.13* | 0.14* | 0.14* | 0.16* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 1062.6% | 507 | -52.70 | 518 | 416 | 389 | -261 | 602 | 700 | 104 | 787 | 763 | 1,155 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.0% | 26,568 | 26,845 | 28,193 | 25,157 | 24,598 | 24,554 | 24,854 | 25,081 | 23,614 | 23,877 | 23,807 | 24,470 | 23,855 | 24,619 | 24,934 | 25,512 | 26,119 | 27,234 | 27,484 | 26,288 | 26,446 |
Current Assets | -1.5% | 6,756 | 6,859 | 8,454 | 10,432 | 9,763 | 9,791 | 9,766 | 9,741 | 7,916 | 7,857 | 7,162 | 7,184 | 6,720 | 6,887 | 7,843 | 8,494 | 8,007 | 8,382 | 8,448 | 7,910 | 8,943 |
Cash Equivalents | 2.3% | 1,074 | 1,050 | 2,288 | 2,618 | 2,898 | 3,419 | 3,676 | 2,647 | 1,749 | 2,261 | 1,542 | 1,742 | 1,218 | 1,331 | 2,225 | 2,385 | 2,591 | 2,914 | 2,344 | 1,723 | 2,243 |
Inventory | -0.4% | 2,517 | 2,527 | 2,982 | 1,334 | 1,281 | 1,344 | 1,375 | 1,294 | 1,215 | 1,352 | 1,348 | 1,255 | 1,172 | 1,069 | 1,028 | 953 | 859 | 804 | 752 | 777 | 770 |
Net PPE | -1.0% | 3,275 | 3,310 | 3,302 | 3,307 | 3,301 | 3,299 | 3,266 | 3,355 | 3,373 | 3,416 | 3,411 | 3,442 | 3,438 | 3,412 | 3,360 | 3,331 | 3,282 | 3,247 | 3,138 | 3,078 | 3,014 |
Goodwill | 0.1% | 6,227 | 6,219 | 474 | 5,754 | 5,752 | 5,749 | 5,741 | 5,750 | 5,758 | 5,761 | 5,761 | 5,764 | 5,763 | 5,762 | 5,756 | 5,751 | 5,752 | 5,758 | 5,746 | 5,749 | 5,640 |
Liabilities | -5.7% | 11,355 | 12,045 | 13,714 | 10,696 | 10,811 | 11,166 | 12,087 | 13,218 | 12,394 | 12,918 | 12,925 | 13,256 | 13,192 | 13,933 | 14,190 | 14,223 | 13,582 | 13,895 | 13,492 | 13,339 | 12,624 |
Current Liabilities | -6.2% | 3,223 | 3,434 | 5,022 | 3,187 | 3,015 | 3,273 | 3,926 | 5,018 | 3,947 | 4,298 | 4,212 | 3,347 | 3,166 | 3,742 | 3,804 | 3,447 | 4,639 | 4,864 | 4,432 | 3,211 | 3,149 |
Long Term Debt | -7.3% | 6,290 | 6,788 | 6,786 | 6,285 | 6,283 | 6,281 | 6,279 | 6,277 | 6,276 | 6,274 | 6,272 | 7,269 | 7,267 | 7,426 | 7,425 | 7,424 | 4,460 | 4,459 | 4,458 | 5,949 | 5,943 |
Shareholder's Equity | 2.8% | 15,213 | 14,799 | 14,484 | 14,461 | 13,787 | 13,388 | 12,767 | 11,863 | 11,221 | 10,960 | 10,882 | 11,215 | 10,663 | 10,686 | 10,745 | 11,289 | 12,537 | 13,339 | 13,992 | 12,949 | 13,822 |
Retained Earnings | 2.2% | 18,021 | 17,628 | 17,378 | 17,446 | 16,854 | 16,467 | 15,916 | 14,960 | 14,216 | 13,912 | 13,544 | 13,901 | 13,834 | 13,976 | 13,961 | 14,467 | 15,673 | 16,455 | 17,065 | 16,183 | 17,027 |
Additional Paid-In Capital | 8.9% | 330 | 303 | 242 | 171 | 91.00 | 73.00 | - | - | 119 | 68.00 | - | - | - | - | - | - | 0.00 | - | - | - | - |
Shares Outstanding | 0.2% | 145 | 145 | 145 | 145 | 144 | 144 | 146 | 146 | 147 | 147 | 148 | 150 | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | -4.10 | -6.40 | -9.60 | -9.50 | -8.70 | -9.10 | -21.60 | 64.00 | 452 | 463 | -19.00 | -14.20 | -14.00 | -19.50 | -10.00 | -4.10 | -4.10 | -4.10 | -7.90 |
Float | - | - | - | - | 41,191 | - | - | - | 29,398 | - | - | - | 51,265 | - | - | - | 42,103 | - | - | - | 43,010 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 4325.6% | 553 | 13.00 | 592 | 487 | 455 | -175 | 661 | 737 | 162 | 838 | 805 | 1,227 | 769 | -367 | 1,181 | 1,949 | 1,467 | 1,960 | 1,695 | 1,964 | 1,460 |
Share Based Compensation | -61.9% | 73.00 | 191 | -64.80 | -74.10 | 76.00 | 189 | -65.70 | -58.00 | 68.00 | 170 | -57.60 | -55.80 | 70.00 | 132 | -35.40 | -49.50 | 68.00 | 139 | -47.80 | -55.00 | 46.00 |
Cashflow From Investing | 89.9% | -66.00 | -652 | -1,742 | -753 | -953 | -141 | 1,672 | 694 | -648 | -112 | -233 | -152 | -64.70 | -166 | -52.40 | -832 | 443 | 708 | -365 | -110 | 239 |
Cashflow From Financing | 32.0% | -439 | -646 | 849 | -9.80 | -43.40 | -7.40 | -1,251 | -471 | -16.50 | 10.00 | -746 | -564 | -785 | -401 | -1,312 | -1,313 | -2,245 | -2,116 | -689 | -2,375 | -679 |
Buy Backs | - | - | - | - | - | - | - | 250 | 500 | - | - | 750 | 450 | 600 | 400 | 1,250 | 2,809 | 2,220 | 2,093 | 718 | 2,402 | 656 |
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenue | $ 2,290.5 | $ 2,463.0 |
Cost and expenses: | ||
Cost of sales, excluding amortization and impairment of acquired intangible assets | 542.2 | 662.8 |
Research and development | 452.9 | 570.6 |
Selling, general and administrative | 581.5 | 605.0 |
Amortization and impairment of acquired intangible assets | 78.3 | 50.2 |
Collaboration profit sharing/(loss reimbursement) | 65.6 | 57.1 |
Restructuring charges | 11.5 | 9.6 |
Other (income) expense, net | 93.7 | 69.4 |
Total cost and expense | 1,825.7 | 2,024.7 |
Income before income tax (benefit) expense | 464.8 | 438.3 |
Income tax (benefit) expense | 71.4 | 50.7 |
Net income | 393.4 | 387.6 |
Net income (loss) attributable to noncontrolling interests, net of tax | 0.0 | (0.3) |
Net income attributable to Biogen Inc. | $ 393.4 | $ 387.9 |
Net income per share: | ||
Basic earnings per share attributable to Biogen Inc. | $ 2.71 | $ 2.69 |
Diluted earnings per share attributable to Biogen Inc. | $ 2.70 | $ 2.67 |
Weighted-average shares used in calculating: | ||
Basic earnings per share attributable to Biogen Inc. | 145.2 | 144.4 |
Diluted earnings per share attributable to Biogen Inc. | 145.9 | 145.2 |
Product, net | ||
Total revenue | $ 1,711.9 | $ 1,763.3 |
Revenue from anti-CD20 therapeutic programs | ||
Total revenue | 394.0 | 399.5 |
Contract manufacturing, royalty and other revenue | ||
Total revenue | $ 184.6 | $ 300.2 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,074.4 | $ 1,049.9 |
Inventory | 2,516.8 | 2,527.4 |
Other current assets | 1,165.3 | 1,182.0 |
Total current assets | 6,756.2 | 6,859.3 |
Property, plant and equipment, net | 3,275.3 | 3,309.7 |
Operating lease assets | 428.1 | 420.0 |
Intangible assets, net | 8,284.7 | 8,363.0 |
Goodwill | 6,227.4 | 6,219.2 |
Deferred tax asset | 898.3 | 928.6 |
Investments and other assets | 697.6 | 745.0 |
Total assets | 26,567.6 | 26,844.8 |
Current liabilities: | ||
Current portion of term loan | 250.0 | 150.0 |
Taxes payable | 231.2 | 257.4 |
Accounts payable | 387.0 | 403.3 |
Accrued expense and other | 2,354.6 | 2,623.6 |
Total current liabilities | 3,222.8 | 3,434.3 |
Notes payable and term loan | 6,290.1 | 6,788.2 |
Deferred tax liability | 658.1 | 641.8 |
Long-term operating lease liabilities | 406.5 | 400.0 |
Other long-term liabilities | 777.1 | 781.1 |
Total liabilities | 11,354.6 | 12,045.4 |
Commitments, contingencies and guarantees | ||
Biogen Inc. shareholders’ equity: | ||
Preferred stock, par value $0.000 per share | 0.0 | 0.0 |
Common stock, par value $— per share | 0.1 | 0.1 |
Additional paid-in capital | 329.5 | 302.5 |
Accumulated other comprehensive income (loss) | (160.5) | (153.7) |
Retained earnings | 18,021.0 | 17,627.6 |
Treasury stock, at cost | (2,977.1) | (2,977.1) |
Total equity | 15,213.0 | 14,799.4 |
Total liabilities and equity | 26,567.6 | 26,844.8 |
Nonrelated Party | ||
Current assets: | ||
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively | 1,604.5 | 1,664.1 |
Related Party | ||
Current assets: | ||
Accounts receivable, net of allowance for doubtful accounts of $2.2 and $2.4, respectively | $ 395.2 | $ 435.9 |
 | Mr. Christopher A. Viehbacher |
---|---|
 | biogen.com |
 | Pharmaceuticals |
 | 8725 |